MedTrace Logo

Colorectal Cancer Immunomonitoring Combined With Radiofrequency ablatIon

NCT04420013 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2020-08-18

No results posted yet for this study

Summary

The primary objective of the study aims to compare soluble CD154 (CD40L) levels before and after radiofrequency ablation (RFA) in patients with colorectal cancer (CRC) liver metastases.

The secondary objectives aims:

* to compare soluble CD154 (sCD40-L) levels before and after treatment by RFA or surgery alone in patients with CRC liver metastases;
* to study the feasibility and reliability of soluble CD154 (sCD40-L) levels to detect and quantify the induction of immun response in CRC liver metastases patients after RFA;
* to study the impact of surgery on plasma soluble CD154 levels;
* to study association between CD154 expression level before and after RFA in CRC liver metastases patients and relapses rate at 1 year.

Conditions

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Robert MALAFOSSE, MD · Department of digestive surgery, Ambroise Paré Hospital, APHP

  • Cindy Neuzillet, MD · Department of digestive surgery, Ambroise Paré Hospital, APHP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2022-03-31
Completion
2022-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04420013 on ClinicalTrials.gov